EBITDA Margin % is calculated as EBITDA divided by its Revenue. Tanvex BioPharma's EBITDA for the
three
months ended in Dec. 2025 was NT$-321.3 Mil. Tanvex BioPharma's Revenue for the
three
months ended in Dec. 2025 was NT$179.0 Mil. Therefore, Tanvex BioPharma's EBITDA margin for the quarter that ended in Dec. 2025 was -179.57%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Tanvex BioPharma EBITDA Margin % Related Terms
Tanvex BioPharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Tanvex BioPharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6541 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Tanvex BioPharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tanvex BioPharma EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tanvex BioPharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Tanvex BioPharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tanvex BioPharma (TPE:6541) has a EBITDA Margin % of -179.57% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tanvex BioPharma and its competitors. According to the industry distribution chart, Tanvex BioPharma ranks #613 out of 938 companies in the Biotechnology industry, placing it in the top 65.4%.
Is Tanvex BioPharma's EBITDA Margin % too high?
Tanvex BioPharma's current EBITDA Margin % is -179.57%. Based on the distribution chart, Tanvex BioPharma ranks #613 out of 938 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Tanvex BioPharma has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tanvex BioPharma's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Tanvex BioPharma ranks #613 out of 938 companies for EBITDA Margin %. This places Tanvex BioPharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tanvex BioPharma and its competitors. Tanvex BioPharma's current EBITDA Margin % is -179.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tanvex BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Tanvex BioPharma (TPE:6541) is currently considered Possible Value Trap. The stock's GF Value™ is NT$254.61, compared to a current price of NT$41.40 — trading 83.7% below its estimated fair value. The current EBITDA Margin % is -179.57%. Tanvex BioPharma's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Tanvex BioPharma (TPE:6541), the current EBITDA Margin % is -179.57% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tanvex BioPharma (TPE:6541) Overvalued in 2026?
Based on GuruFocus' analysis, Tanvex BioPharma stock appears to be undervalued.
The current stock price of NT$41.40 is trading 83.7% below its estimated GF Value™ of NT$254.61.
GuruFocus considers Tanvex BioPharma to be Possible Value Trap.
Key valuation signals for TPE:6541:
EBITDA Margin %: -179.57%
GF Value™: NT$254.61 vs. price of NT$41.40 (83.7% below fair value)
No single metric tells the full story. See the TPE:6541 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company operates in Asia, America, Europe, and Australia. The company generates a majority of its revenue from the USA.
57GF Score
Get the complete analysis for TPE:6541
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6541 has been successfully added to your 
